Alzamend Neuro, Inc. (ALZN)
1.13
+0.01
(+0.89%)
USD |
NASDAQ |
Oct 23, 16:00
1.09
-0.04
(-3.54%)
Pre-Market: 09:12
Alzamend Neuro EPS Diluted (Quarterly) : -0.6759 for July 31, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -0.6759 |
| April 30, 2026 | -0.7382 |
| January 31, 2026 | -0.578 |
| October 31, 2025 | -0.296 |
| July 31, 2025 | -1.283 |
| April 30, 2025 | -2.221 |
| January 31, 2025 | -1.695 |
| October 31, 2024 | -0.3855 |
| July 31, 2024 | -1.253 |
| April 30, 2024 | -1.238 |
| January 31, 2024 | -3.774 |
| October 31, 2023 | -4.427 |
| Date | Value |
|---|---|
| July 31, 2023 | -5.376 |
| April 30, 2023 | -5.13 |
| January 31, 2023 | -8.277 |
| October 31, 2022 | -4.785 |
| July 31, 2022 | -4.674 |
| April 30, 2022 | -6.078 |
| January 31, 2022 | -4.282 |
| October 31, 2021 | -6.078 |
| July 31, 2021 | -4.005 |
| January 31, 2021 | -1.932 |
| October 31, 2020 | -2.380 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.027M |
| Total Expenses (Quarterly) | 3.027M |
| Enterprise Value | -2.138M |
| Earnings Yield | -202.5% |
| Normalized Earnings Yield | -202.48 |